

Material Safety Data Sheet

SDS DATE: October 01, 2021

SECTION 1: PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME: Recombinant Human R³ IGF-1

PRODUCT CODES: MBS845116

RESTRICTIONS ON USE: For laboratory research purposes. Not for drug or household use.

7 CAD5 BM MyBioSource, Inc.
P.O.Box 153308
San Diego, CA 92195-3308 USA
Tel: 1.858.633.0165
Fax: 1.858.633.0166
Email: sales@mybiosource.com

SECTION 2: HAZARDS IDENTIFICATION

Product name	Description	Amount	Safety Information
Recombinant Human R ³ IGF-1	Lyophilized	4216-100:100µg 4216-1MG: 1 mg 4216-5MG: 5 mg 4216-20MG: 20 mg 4216-50MG: 50 mg 4216-1G: 1 g	No hazards

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

No components need to be disclosed according to the applicable regulations.

SECTION 4: FIRST AID MEASURES

If inhaled: If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact: Wash off with soap and plenty of water.
In case of eye contact: Flush eyes with water as a precaution.
If swallowed: Never give anything by mouth to an unconscious person. Rinse mouth with water.

SECTION 5: FIRE-FIGHTING MEASURES

Condition of flammability: Not flammable or combustible.
Suitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for fire-fighters: Wear self-contained breathing apparatus for firefighting if necessary.
Hazardous combustion products: Hazardous decomposition products formed under fire conditions— decomposition products not known.

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personal precautions: Avoid dust formation. Avoid breathing vapors, mist, gas, or dust.
Environmental precautions: Do not let product enter drains.
Methods for cleaning up: Sweep up and shovel. Keep in suitable, closed containers for disposal.

SECTION 7: HANDLING AND STORAGE

Precautions for safe handling: Centrifuge the vial prior to opening. Provide appropriate exhaust ventilation at places where dust is formed.
Normal measures for preventive fire protection.
Conditions for safe storage: The lyophilized IGF-1 is best stored desiccated below 0°C. Reconstituted IGF1 should be stored at working aliquots at 20°C. Avoid freeze/thaw cycles.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

Contains no substances with occupational exposure limit values.

Personal protective equipment

Respiratory protection

Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Hand protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Eye protection

Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin and body protection

Choose body protection in relation to its type, to the concentration and amount of dangerous substance, and to the specific workplace. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Hygiene measures

General industrial hygiene practice.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

Property	Recombinant Human R ³ IGF-1
Appearance:	Lyophilized
pH:	No data available
Water Solubility:	No data available
Other Solubility:	No data available
Boiling Point (°C):	No data available
Melting Point (°C):	No data available
Flash Point (°C):	No data available
Ignition Temperature (°C):	No data available
Density:	No data available

SECTION 10: STABILITY AND REACTIVITY

Property	Recombinant Human R ³ IGF-1
Chemical stability	Stable under recommended storage conditions
Conditions to avoid:	No data available
Materials to avoid:	No data available
Hazardous decomposition products:	No data available

SECTION 11: TOXICOLOGICAL INFORMATION

Recombinant Human R³ IGF-1 :

Acute toxicity: No data available

Skin corrosion/irritation: No data available

Serious eye damage/eye irritation: No data available

Respiratory or skin sensitization: No data available

Germ cell mutagenicity: No data available

Carcinogenicity:

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

Reproductive toxicity: No data available

Teratogenicity: No data available

Specific target organ toxicity – single exposure (GHS): No data available

Specific target organ toxicity – repeated exposure (GHS): No data available

Aspiration hazard: No data available

Potential Health Effects

Inhalation: May be harmful if inhaled. May cause respiratory tract irritation.

Skin: May be harmful if absorbed through skin. May cause skin irritation.

Eyes: May cause eye irritation.

Ingestion: May be harmful if swallowed.

Signs and Symptoms of Exposure: To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

Synergistic effects: No data available

Additional information: RTECS: Not available

SECTION 12: ECOLOGICAL INFORMATION

Recombinant Human R³ IGF-1 :

Persistence and degradability: No data available

Toxicity: No data available
Bioaccumulative potential: No data available
Mobility in soil: No data available
PBT and vPvB assessment: No data available
Other adverse effects: No data available

SECTION 13: DISPOSAL CONSIDERATIONS

Product: Observe all federal, state, and local environmental regulations.
Contaminated packaging: Dispose of as unused product.

SECTION 14: TRANSPORT INFORMATION

Recombinant Human R³ IGF-1 :

DOT (US): Not dangerous goods.

IMDG: Not dangerous goods.

IATA: Not dangerous goods.

SECTION 15: REGULATORY INFORMATION

Recombinant Human R³ IGF-1 :

OSHA Hazards: No known OSHA hazards

SARA 302 Components: SARA 302: No chemical in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components: SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title II, Section 313.

SARA 311/312 Hazards: No SARA Hazards

Massachusetts Right To Know Components: No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components: No components are subject to the Pennsylvania Right to Know Act.

New Jersey Right To Know Components: No components are subject to the New Jersey Right to Know Act.

California Prop. 65 Components: This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

EU regulations: This product is not classified according to the EU regulations.

Component	Risk Phrases	Safety Phrases
Recombinant Human R ³ IGF-1	--	--

SECTION 16: OTHER INFORMATION

DISCLAIMER:

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. MyBioSource, Inc., shall not be held liable for any damage resulting from handling or from contact with the above product. See reverse side of invoice or packing slip for additional terms and conditions of sale.